{
  "table_name": "OPEN_TARGETS_PLATFORM.KNOWNDRUGSAGGREGATED",
  "table_fullname": "OPEN_TARGETS_PLATFORM_2.OPEN_TARGETS_PLATFORM.KNOWNDRUGSAGGREGATED",
  "column_names": [
    "adresses_url",
    "id_médicament",
    "état",
    "noms_commerciaux",
    "étiquette",
    "id_cible",
    "nom_approuvé",
    "ancêtres",
    "nom_cible",
    "phase",
    "nom_préféré",
    "synonymes",
    "type_médicament",
    "symbole_approuvé",
    "id_maladie",
    "mécanisme_d_action",
    "classe_cible"
  ],
  "column_types": [
    "VARIANT",
    "TEXT",
    "TEXT",
    "VARIANT",
    "TEXT",
    "TEXT",
    "TEXT",
    "VARIANT",
    "TEXT",
    "FLOAT",
    "TEXT",
    "VARIANT",
    "TEXT",
    "TEXT",
    "TEXT",
    "TEXT",
    "VARIANT"
  ],
  "description": [
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null
  ],
  "sample_rows": [
    {
      "id_médicament": "CHEMBL409",
      "id_cible": "ENSG00000169083",
      "id_maladie": "EFO_0003869",
      "phase": 2.0,
      "état": "Recruiting",
      "adresses_url": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT06365788\"\n      }\n    }\n  ]\n}",
      "ancêtres": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"MONDO_0021350\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"EFO_0010285\"\n    },\n    {\n      \"element\": \"EFO_0009483\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "étiquette": "breast neoplasm",
      "symbole_approuvé": "AR",
      "nom_approuvé": "androgen receptor",
      "classe_cible": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "nom_préféré": "BICALUTAMIDE",
      "noms_commerciaux": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "synonymes": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "type_médicament": "Small molecule",
      "mécanisme_d_action": "Androgen Receptor antagonist",
      "nom_cible": "Androgen Receptor"
    },
    {
      "id_médicament": "CHEMBL409",
      "id_cible": "ENSG00000169083",
      "id_maladie": "MONDO_0008315",
      "phase": 1.0,
      "état": "Terminated",
      "adresses_url": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT01642732\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00702923\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00924807\"\n      }\n    }\n  ]\n}",
      "ancêtres": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"EFO_0009555\"\n    },\n    {\n      \"element\": \"EFO_0007355\"\n    },\n    {\n      \"element\": \"MONDO_0024582\"\n    },\n    {\n      \"element\": \"MONDO_0002149\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"EFO_1000051\"\n    },\n    {\n      \"element\": \"EFO_0009602\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0021259\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"EFO_0000512\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "étiquette": "prostate cancer",
      "symbole_approuvé": "AR",
      "nom_approuvé": "androgen receptor",
      "classe_cible": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "nom_préféré": "BICALUTAMIDE",
      "noms_commerciaux": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "synonymes": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "type_médicament": "Small molecule",
      "mécanisme_d_action": "Androgen Receptor antagonist",
      "nom_cible": "Androgen Receptor"
    },
    {
      "id_médicament": "CHEMBL409",
      "id_cible": "ENSG00000169083",
      "id_maladie": "MONDO_0002158",
      "phase": 2.0,
      "état": "Completed",
      "adresses_url": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00012090\"\n      }\n    }\n  ]\n}",
      "ancêtres": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"MONDO_0002149\"\n    },\n    {\n      \"element\": \"MONDO_0021092\"\n    },\n    {\n      \"element\": \"EFO_0009548\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"EFO_1000051\"\n    },\n    {\n      \"element\": \"MONDO_0021148\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"EFO_0000512\"\n    },\n    {\n      \"element\": \"EFO_0009549\"\n    },\n    {\n      \"element\": \"EFO_1001331\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "étiquette": "fallopian tube cancer",
      "symbole_approuvé": "AR",
      "nom_approuvé": "androgen receptor",
      "classe_cible": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "nom_préféré": "BICALUTAMIDE",
      "noms_commerciaux": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "synonymes": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "type_médicament": "Small molecule",
      "mécanisme_d_action": "Androgen Receptor antagonist",
      "nom_cible": "Androgen Receptor"
    },
    {
      "id_médicament": "CHEMBL409",
      "id_cible": "ENSG00000169083",
      "id_maladie": "EFO_0001663",
      "phase": 2.0,
      "état": "Completed",
      "adresses_url": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00298155\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00586898\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00486642\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00108732\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT02614859\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00170157\"\n      }\n    }\n  ]\n}",
      "ancêtres": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"EFO_0009555\"\n    },\n    {\n      \"element\": \"EFO_0007355\"\n    },\n    {\n      \"element\": \"MONDO_0024582\"\n    },\n    {\n      \"element\": \"MONDO_0002149\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"EFO_1000051\"\n    },\n    {\n      \"element\": \"EFO_0009602\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0021259\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"MONDO_0008315\"\n    },\n    {\n      \"element\": \"EFO_0000512\"\n    },\n    {\n      \"element\": \"EFO_0000313\"\n    },\n    {\n      \"element\": \"EFO_0006858\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "étiquette": "prostate carcinoma",
      "symbole_approuvé": "AR",
      "nom_approuvé": "androgen receptor",
      "classe_cible": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "nom_préféré": "BICALUTAMIDE",
      "noms_commerciaux": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "synonymes": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "type_médicament": "Small molecule",
      "mécanisme_d_action": "Androgen Receptor antagonist",
      "nom_cible": "Androgen Receptor"
    },
    {
      "id_médicament": "CHEMBL409",
      "id_cible": "ENSG00000169083",
      "id_maladie": "EFO_0000616",
      "phase": 4.0,
      "état": null,
      "adresses_url": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ATC\",\n        \"url\": \"https://www.whocc.no/atc_ddd_index/?code=L02BB03\"\n      }\n    }\n  ]\n}",
      "ancêtres": "{\n  \"list\": [\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    }\n  ]\n}",
      "étiquette": "neoplasm",
      "symbole_approuvé": "AR",
      "nom_approuvé": "androgen receptor",
      "classe_cible": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "nom_préféré": "BICALUTAMIDE",
      "noms_commerciaux": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "synonymes": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "type_médicament": "Small molecule",
      "mécanisme_d_action": "Androgen Receptor antagonist",
      "nom_cible": "Androgen Receptor"
    }
  ]
}